FCM
Farallon Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $134M | Buy |
4,646,098
+41,000
| +0.9% | +$1.18M | 0.58% | 38 |
|
|
2025
Q1 | $154M | Buy |
4,605,098
+530,000
| +13% | +$17.8M | 0.77% | 37 |
|
|
2024
Q4 | $208M | Buy |
4,075,098
+2,913,098
| +251% | +$149M | 0.93% | 34 |
|
|
2024
Q3 | $59.4M | Buy |
1,162,000
+665,000
| +134% | +$34M | 0.26% | 53 |
|
|
2024
Q2 | $22.3M | Buy |
497,000
+492,000
| +9,840% | +$22M | 0.1% | 66 |
|
|
2024
Q1 | $234K | Sell |
5,000
-117,904
| -96% | -$5.52M | ﹤0.01% | 136 |
|
|
2023
Q4 | $4.37M | Sell |
122,904
-239,000
| -66% | -$8.5M | 0.02% | 93 |
|
|
2023
Q3 | $10.8M | Buy |
+361,904
| New | +$10.8M | 0.05% | 84 |
|
|
2019
Q1 | – | Sell |
-95,365
| Closed | -$2.86M | – | 96 |
|
|
2018
Q4 | $2.86M | Sell |
95,365
-46,450
| -33% | -$1.39M | 0.02% | 89 |
|
|
2018
Q3 | $4.06M | Buy |
+141,815
| New | +$4.06M | 0.02% | 92 |
|